Filing Flows › Health Care › Immucell (ICCC)
Immucell (ICCC) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Immucell (ICCC) Q2 2026 earnings results →
Q2 2026 Revenue up 12% year over year to $7.2M · 26¢ of every $1 of revenue kept as net profit · operating margin 26.9%
Immucell made $7.2M in Q2 2026 (+12% Y/Y). Operating margin 26.9%, net earnings $1.8M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.2M in Q2 2026, up 12% year over year and down 31% from the previous quarter.
Gross margin was 33.9%, down 9.8 points from Q2 2025. Operating profit was $1.9M, a 26.9% margin (up 18.1 points year over year). Of the extra revenue versus Q2 2025, 184% reached operating profit, above the 9% margin then. Operating expenses fell 78% while revenue rose 12%. Net earnings were $1.8M, up 266% year over year. The effective tax rate was 2.4%.
Operating cash flow was $3.0M (up 89% year over year), 165% of net earnings. Non-cash charges added back $471K of depreciation and amortization and $240K of share-based compensation. Working capital and other items added $474K. Capital expenditures of $734K left free cash flow of $2.3M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $7.2M | +12% | 26.9% | $1.8M | $3.0M |
| Q1 2026 | 10-Q | May 14, 2026 | $10.4M | +28% | 19.0% | $1.9M | $3.6M |
| Q4 2025 | 10-K | Mar 30, 2026 | $7.6M | -2% | -0.8% | −$2.8M | $483K |
| Q3 2025 | 10-Q | Nov 13, 2025 | $5.5M | -8% | 0.4% | −$140K | −$1.2M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $6.4M | +18% | 8.8% | $502K | $1.6M |
| Q1 2025 | 10-Q | May 14, 2025 | $8.1M | +11% | 13.9% | $1.4M | $1.6M |
| Q4 2024 | 10-K | Mar 28, 2025 | $7.8M | +52% | 8.0% | $515K | −$3K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Immucell
ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. The Company's practical, science-based solutions help prevent calf scours, one of the most prevalent diseases in neonatal calves worldwide that accounts for 30-40% of pre-weaning mortality in many production systems. The Company’s primary product line, First Defense ® , utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components.
In its own words, from its 10-K, filed Mar 30, 2026.
Immucell against its In Vitro & In Vivo Diagnostic Substances peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +12% against the peers' median +2%. Operating margin: 26.9% against the peers' median -1.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ICCC Immucell | Q2 2026 | $7.2M | +12% | 26.9% |
| IDXX Idexx Laboratories | Q3 2026 | $1.2B | +10% | 33.1% |
| QDEL QuidelOrtho | Q3 2026 | $619M | -12% | -1.2% |
| LNTH Lantheus Holdings | Q3 2026 | $390M | +2% | 8.3% |
| NEOG Neogen | Q1 FY27 | $223M | +6% | -0.8% |
| MYGN Myriad Genetics | Q3 2026 | $203M | -2% | -19.7% |
| TKNO Alpha Teknova | Q3 2026 | $12.7M | +22% | -25.2% |
| NTLA Intellia Therapeutics | Q3 2026 | $7.2M | -48% | n/m |
| AWHL Aspira Women's Health | Q2 2026 | $2.0M | -15% | -89.7% |
Source: Immucell 10-Q on SEC EDGAR · CIK 811641 · In Vitro & In Vivo Diagnostic Substances
13F: who owns ICCC and who is buying
More on ICCC
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results